Scientists might choose indirect delivery instead of direct delivery for a gene therapy primarily because indirect delivery allows scientists to make sure the cells have been correctly modified and are producing the protein.
This approach can facilitate quality control, ensuring that the modified cells exhibit the desired characteristics before they are introduced into the patient's body. It also enables better monitoring of the modified cells throughout the treatment process.